Akari Therapeutics, Plc (NASDAQ:AKTX) is a biotechnology company that focuses on developing treatments for oncology. The company is preparing for a significant change in its stock structure. On March 31, 2026, AKTX will implement a reverse stock split, exchanging 1 share for every 40 shares. This move is part of a broader strategy to maintain compliance with Nasdaq's listing requirements.
In addition to the reverse stock split, Akari is adjusting the ratio of its American Depositary Shares (ADSs) to ordinary shares. The new ratio will be one ADS representing 80,000 ordinary shares, up from the previous 2,000. This change, effective on the same date as the reverse split, aims to help Akari meet Nasdaq's minimum bid price requirement. Deutsche Bank will manage the exchange process for ADS holders.
Currently, AKTX trades at $0.14 on the Nasdaq. The stock has seen a recent increase of 11.45%, with a price change of $0.01. Despite this uptick, the stock has fluctuated between $0.13 and $0.14 yesterday. Over the past year, AKTX has experienced a high of $1.58 and a low of $0.13, reflecting significant volatility.
The market capitalization of AKTX stands at approximately $2.59 million, indicating the company's relatively small size in the biotechnology sector. With a trading volume of 331,620 shares, the stock shows moderate activity in the market. The upcoming changes in stock structure and ADS ratio are crucial for Akari's continued presence on the Nasdaq Capital Market.
